ライフサイエンスコーパス: recurrent breast cancer

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 as a very low detection rate for nonpalpable recurrent breast cancer.

2 whole population of CTCs in 19 patients with recurrent breast cancer.

3 Seventeen patients (36.2%) developed recurrent breast cancer.

4 powerful approach for the early detection of recurrent breast cancer.

5 Costs of PMRT ($11,600) and recurrent breast cancer ($4,250 to 16,200/year) were est

6 he serial samples were from 20 patients with recurrent breast cancer, and 141 samples were from 36 pa

7 supplemental, and total vitamin D intake and recurrent breast cancer, and a nested case-control study

8 Women with recurrent breast cancer are in need of programs to assis

9 Recurrent breast cancers arise from the pool of dissemin

10 se of this study was to quantify the risk of recurrent breast cancer associated with HRT among breast

11 cancer events: 14 patients developed new or recurrent breast cancer at a median time of 139.5 months

12 te a prediction model for early detection of recurrent breast cancer based on metabolic profiles.

13 uant BR RIA can be used as an aid to predict recurrent breast cancer in patients with stage II and II

14 sment of both palpable and clinically occult recurrent breast cancers in autogenous myocutaneous flap

15 Recurrent breast cancer is typically an incurable diseas

16 Detection of a new or recurrent breast cancer lesion relies on physical examin

17 08 consecutive patients with known/suspected recurrent breast cancer on [(18)F]FDG-PET/CT, characteri

18 nformation is available about the effects of recurrent breast cancer on the quality of life of women

19 on the development of a monitoring test for recurrent breast cancer, using metabolite-profiling meth

20 The detection rate for nonpalpable recurrent breast cancer was 0% (exact 95% confidence int

21 rogesterone receptor-positive, metastatic or recurrent breast cancer were enrolled in this prospectiv

22 standard deviation]) with newly diagnosed or recurrent breast cancer were recruited between November

23 erous transformation, as well as invasive or recurrent breast cancer, with dual-specificity radiohybr

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。